In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist

References

• Babbar S, Chanda S, Bley K. (2010). Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 40:807–816.
   PubMed Web of Science ®Google Scholar
• Crespi CL, Miller VP, Penman BW. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188–190.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2010). Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf. Accessed on 05 Jul 2012.
   Google Scholar
• Fahmi OA, Kish M, Boldt S, Obach RS. (2010). Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605–1611.
   PubMed Web of Science ®Google Scholar
• Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–670.
   PubMed Web of Science ®Google Scholar
• Khullar V, Cambronero J, Ströberg P, Angulo J, Boerrigter P, Blauwet MB, Wooning M. (2011). The efficacy and tolerability of mirabegron in patients with overactive bladder – results from a European–Australian Phase III trial. Eur Urol Suppl 10:278–279.
   Web of Science ®Google Scholar
• Krauwinkel WJ, van Gelderen EM, Groen MJ, Schaddelee M, de Koning P. (2010). An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects. Clin Pharmacol Ther 87:S88.
   Google Scholar
• LeCluyse EL, Audus KL, Hochman JH. (1994). Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 266:C1764–C1774.
   PubMed Web of Science ®Google Scholar
• LeCluyse EL, Bullock PL, Parkinson A, Hochman JH. (1996). Cultured rat hepatocytes, in Pharmaceutical Biotechnology. In: Borchardt RT, Wilson G, Smith P, eds. Models for Assessing Drug Absorption and Metabolism Vol. 8. New York: Plenum Press, 121–159.
   Google Scholar
• Madan A, DeHaan R, Mudra D, Carroll K, LeCluyse E, Parkinson A. (1999). Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metab Dispos 27:327–335.
   PubMed Web of Science ®Google Scholar
• Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421–431.
   PubMed Web of Science ®Google Scholar
• Mudra DR, Parkinson A. (2001). Preparation of hepatocytes; Unit 14.2. In: Maines MD, ed. Current Protocols in Toxicology, Volume 1. New York: John Wiley and Sons, Inc.
   Google Scholar
• Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N. (2011). The efficacy and safety of mirabegron in patients with overactive bladder syndrome – results from a North-American Phase III trial. Eur Urol Suppl 10:278.
   Google Scholar
• Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191–197.
   PubMed Web of Science ®Google Scholar
• Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. (2009). In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 37:2045–2054.
   PubMed Web of Science ®Google Scholar
• Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193–209.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. (1996). Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805–816.
   PubMed Web of Science ®Google Scholar
• Robertson P, DeCory HH, Madan A, Parkinson A. (2000). In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 28:664–671.
   PubMed Web of Science ®Google Scholar
• Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. (2007). Effect of ®-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647.
   PubMed Web of Science ®Google Scholar
• Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T. (2012a). Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective ß(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos 40:815–824.
   PubMed Web of Science ®Google Scholar
• Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T. (2012b). Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)-adrenoceptor agonist. Xenobiotica. [Epub ahead of print; 18 April 2012].
   Google Scholar
• Tucker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential–toward a consensus. Pharm Res 18:1071–1080.
   PubMedGoogle Scholar
• US FDA, Center for Drug Evaluation and Research (CDER). (2006). Guidance for industry. Drug interaction studies - study design, data analysis, and implications for dosing and labeling. draft guidance.
   Google Scholar
• US FDA, Center for Drug Evaluation and Research (CDER). (2012). Guidance for industry. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. draft guidance.
   Google Scholar
• Yamaguchi O, Chapple CR. (2007). Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 26:752–756.
   PubMed Web of Science ®Google Scholar